DE60234510D1 - 1h-indazolverbindungen die jnk hemmen - Google Patents

1h-indazolverbindungen die jnk hemmen

Info

Publication number
DE60234510D1
DE60234510D1 DE60234510T DE60234510T DE60234510D1 DE 60234510 D1 DE60234510 D1 DE 60234510D1 DE 60234510 T DE60234510 T DE 60234510T DE 60234510 T DE60234510 T DE 60234510T DE 60234510 D1 DE60234510 D1 DE 60234510D1
Authority
DE
Germany
Prior art keywords
group
group etc
indazone
hemmen
jnk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234510T
Other languages
English (en)
Inventor
Hitoshi Oinuma
Norihito Ohi
Nobuaki Sato
Motohiro Soejima
Hidenori Seshimo
Taro Terauchi
Takashi Doko
Naohiro Kohmura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Application granted granted Critical
Publication of DE60234510D1 publication Critical patent/DE60234510D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60234510T 2001-04-16 2002-04-15 1h-indazolverbindungen die jnk hemmen Expired - Lifetime DE60234510D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001116521 2001-04-16
PCT/JP2002/003735 WO2002083648A1 (en) 2001-04-16 2002-04-15 Novel 1h-indazole compound

Publications (1)

Publication Number Publication Date
DE60234510D1 true DE60234510D1 (de) 2010-01-07

Family

ID=18967246

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234510T Expired - Lifetime DE60234510D1 (de) 2001-04-16 2002-04-15 1h-indazolverbindungen die jnk hemmen

Country Status (10)

Country Link
US (3) US6982274B2 (de)
EP (1) EP1380576B1 (de)
JP (1) JP4535680B2 (de)
KR (1) KR20040007497A (de)
CN (1) CN1300116C (de)
AT (1) ATE449763T1 (de)
AU (1) AU2002255263B2 (de)
CA (1) CA2440842A1 (de)
DE (1) DE60234510D1 (de)
WO (1) WO2002083648A1 (de)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
ATE449763T1 (de) * 2001-04-16 2009-12-15 Eisai R&D Man Co Ltd 1h-indazolverbindungen die jnk hemmen
US20040077702A1 (en) * 2001-09-14 2004-04-22 Wen-Mei Fu Treatment of nuerodegenerative diseases
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
TW200302722A (en) * 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
AU2003207104A1 (en) 2002-02-28 2003-09-09 Eisai Co., Ltd. Novel fused ring indazole compounds
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
KR20050004214A (ko) 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
AU2003259749A1 (en) 2002-08-12 2004-02-25 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
TW200409759A (en) * 2002-09-25 2004-06-16 Wyeth Corp Substituted 4-(indazol-3-yl)phenols
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
WO2004089366A1 (en) * 2003-04-10 2004-10-21 Pfizer Japan, Inc. Bicyclic compounds as nr2b receptor antagonists
ES2374272T3 (es) * 2003-06-19 2012-02-15 Glaxosmithkline Llc Derivados de 5-(acilamino)indazol como inhibidores de quinasas.
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
ATE553092T1 (de) * 2003-07-30 2012-04-15 Kyowa Hakko Kirin Co Ltd Indazolderivate
AU2004260759B2 (en) * 2003-07-30 2010-04-22 Kyowa Hakko Kirin Co., Ltd. Protein kinase inhibitors
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
ATE546452T1 (de) 2003-09-23 2012-03-15 Vertex Pharma Pyrazolopyrrolderivate als proteinkinaseinhibitoren
US20070060595A1 (en) * 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
WO2005051942A1 (en) * 2003-11-19 2005-06-09 Signal Pharmaceuticals, Llc Indazole compounds and methods of use thereof as protein kinase inhibitors
US7544707B2 (en) 2003-12-22 2009-06-09 Eli Lilly And Company Bicyclic derivatives as PPAR modulators
EP1697336B1 (de) * 2003-12-22 2007-12-19 Basilea Pharmaceutica AG Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen
RU2006134022A (ru) * 2004-02-27 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные индазола и содержащие их фармацевтические композиции
US7378532B2 (en) 2004-03-26 2008-05-27 Yung Shin Pharmaceutical Ind. Co., Ltd. Fused pyrazolyl compound
GB0409080D0 (en) * 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
MX2007001126A (es) * 2004-07-27 2007-09-25 Sgx Pharmaceuticals Inc Moduladores de heterociclo cinasa de anillo fusionado.
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US7803824B2 (en) 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US7605272B2 (en) * 2005-01-27 2009-10-20 Kyowa Hakko Kirin Co., Ltd. IGF-1R inhibitor
JP2008530028A (ja) * 2005-02-24 2008-08-07 テバ ファーマシューティカル インダストリーズ リミティド リネゾリッド中間体の調製方法
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
KR20080103996A (ko) * 2006-02-16 2008-11-28 쉐링 코포레이션 Ｅｒｋ 억제제로서 피롤리딘 유도체
WO2007126964A2 (en) * 2006-03-31 2007-11-08 Schering Corporation Kinase inhibitors
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PL2007756T3 (pl) 2006-04-07 2016-01-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP
CN101484427A (zh) 2006-06-30 2009-07-15 协和发酵麒麟株式会社 Abl激酶抑制剂
CN101484426A (zh) * 2006-06-30 2009-07-15 协和发酵麒麟株式会社 Aurora抑制剂
DE102006030479A1 (de) 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US20080153810A1 (en) * 2006-11-15 2008-06-26 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
CA2672960A1 (en) * 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
US8278337B2 (en) 2006-12-20 2012-10-02 Merck Sharp & Dohme Substituted pyridines that are JNK inhibitors
CA2680122A1 (en) 2007-03-05 2008-09-18 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
DE102007032739A1 (de) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
US7919581B2 (en) 2007-07-31 2011-04-05 Burnham Institute For Medical Research Bi-dentate compounds as kinase inhibitors
RU2437883C1 (ru) 2007-08-17 2011-12-27 Эл Джи Лайф Сайенсиз Лтд. Соединения индола и индазола в качестве ингибитора некроза клетки
DE102007041116A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh 1,3-Dihydro-isoindolderivate
RU2525389C2 (ru) * 2008-02-21 2014-08-10 Мерк Шарп И Доум Корп. Соединения, которые являются ингибиторами erk
MX2010010262A (es) * 2008-03-20 2010-12-06 Abbott Lab Metodos para la elaboracion de agentes para el sistema nervioso central que son antagonistas del trpv1.
US20110278332A1 (en) * 2009-03-26 2011-11-17 Protexer, Inc. Shoe cover removal apparatus
DE102008061214A1 (de) 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate
WO2010111060A1 (en) * 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
DE102009054302A1 (de) 2009-11-23 2011-05-26 Merck Patent Gmbh Chinazolinderivate
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
EP2584903B1 (de) * 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
EP2613782B1 (de) * 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
AU2011295725B2 (en) 2010-09-03 2015-03-26 Forma Tm, Llc. Novel compounds and compositions for the inhibition of NAMPT
DE102010046837A1 (de) 2010-09-29 2012-03-29 Merck Patent Gmbh Phenylchinazolinderivate
JP2014500277A (ja) 2010-12-09 2014-01-09 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としての二環式化合物
WO2012087772A1 (en) * 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
JP2014510105A (ja) 2011-03-22 2014-04-24 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としてのアゾール化合物
US9580390B2 (en) 2011-10-12 2017-02-28 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
KR101511771B1 (ko) * 2011-12-20 2015-04-14 주식회사 엘지생명과학 세포괴사 저해제로서의 인돌 및 인다졸 화합물
NZ631258A (en) 2012-04-25 2016-11-25 Takeda Pharmaceuticals Co Nitrogenated heterocyclic compound
IL289834B1 (en) 2012-06-13 2024-03-01 Incyte Holdings Corp Conversion of tricyclic compounds as FGFR inhibitors
US8980934B2 (en) 2012-06-22 2015-03-17 University Health Network Kinase inhibitors and method of treating cancer with same
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
WO2014014841A1 (en) 2012-07-16 2014-01-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
TW201427970A (zh) * 2012-10-12 2014-07-16 Univ Health Network 激酶抑制劑及使用其治療癌症的方法
WO2014134772A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9440952B2 (en) 2013-03-04 2016-09-13 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134776A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9834520B2 (en) 2013-03-14 2017-12-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
SI2986610T1 (en) 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as inhibitors of FGFR
JP6427491B2 (ja) 2013-07-03 2018-11-21 武田薬品工業株式会社 複素環化合物
EP3018123B1 (de) 2013-07-03 2023-05-10 Takeda Pharmaceutical Company Limited Amidverbindung
AU2014297912A1 (en) 2013-07-31 2016-02-25 Council Of Scientific & Industrial Research Novel indazole compounds and a process for the preparation thereof
WO2015154169A1 (en) 2014-04-09 2015-10-15 The University Of British Columbia Binding function3 (bf3) site compounds as therapeutics and methods for their use
SI3424534T1 (sl) 2014-04-15 2021-08-31 Vertex Pharmaceutical Incorporated Farmacevtski sestavki za zdravljenje bolezni, ki jih povzroča regulator transmembranske prevodnosti pri cistični fibrozi
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN105061316B (zh) * 2015-07-17 2017-12-22 苏州大学 稠环类化合物、制备方法和用途
CN108368057B (zh) * 2015-08-20 2022-03-15 捷思英达医药技术（上海）有限公司 作为erk抑制剂的吡唑并稠合的杂环化合物
KR102484810B1 (ko) * 2016-05-25 2023-01-05 (주)아모레퍼시픽 피부 미백용 조성물
EP3584241B1 (de) * 2017-02-14 2023-04-26 FUJIFILM Corporation Verfahren zur herstellung einer indazolverbindung und indazolverbindung
KR102615821B1 (ko) * 2017-04-11 2023-12-21 선샤인 레이크 파르마 컴퍼니 리미티드 불소-치환된 인다졸 화합물 및 이의 용도
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2018234354A1 (en) * 2017-06-20 2018-12-27 Grünenthal GmbH NOVEL SUBSTITUTED 3-INDOLE AND 3-INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
WO2018234353A1 (en) * 2017-06-20 2018-12-27 Grünenthal GmbH NOVEL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
EP3788047A2 (de) 2018-05-04 2021-03-10 Incyte Corporation Feste formen eines fgfr-inhibitors und verfahren zur herstellung davon
KR102195348B1 (ko) * 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
EP3906029A4 (de) 2018-12-31 2022-09-21 Biomea Fusion, LLC Inhibitoren der menin-mll-interaktion
US11084825B2 (en) 2018-12-31 2021-08-10 Biomea Fusion, Llc Substituted pyridines as irreversible inhibitors of menin-MLL interaction
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20220340568A1 (en) * 2019-09-11 2022-10-27 Ohio State Innovation Foundation Kinase inhibitors for the treatment of neurodegenerative diseases
WO2021067374A1 (en) * 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022007163A2 (pt) 2019-10-14 2022-08-23 Incyte Corp Heterociclos bicíclicos como inibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
EP4352059A1 (de) 2021-06-09 2024-04-17 Incyte Corporation Tricyclische heterocyclen als fgfr-inhibitoren
CN113999211B (zh) * 2021-11-23 2022-11-29 郑州大学 一类特异性抗前列腺癌活性的含1,2,3-三氮唑的吲唑骨架衍生物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1266763B (de) * 1965-07-27 1968-04-25 Kalle Ag Verfahren zur Herstellung von in 3-Stellung substituierten Indol- und Indazolderivaten
JPS5944314B2 (ja) 1975-01-15 1984-10-29 中外製薬株式会社 インダゾ−ル誘導体の製法
JPS604824B2 (ja) 1976-04-02 1985-02-06 中外製薬株式会社 インダゾール誘導体
JPS5615287A (en) * 1979-07-16 1981-02-14 Chugai Pharmaceut Co Ltd Pyrazoloindazole derivative and its preparation
JPH01180878A (ja) 1988-01-11 1989-07-18 Yoshitomi Pharmaceut Ind Ltd 縮合ピラゾール化合物
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
GB8811299D0 (en) * 1988-05-12 1988-06-15 Grayshan R Indazole derivatives
US4954503A (en) 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
US5051430A (en) 1990-09-10 1991-09-24 Hoechst-Roussel Pharmaceuticals Incorporated 3-(1H-indazol-3-yl)-4-pyridinamines
JPH06206872A (ja) 1992-10-06 1994-07-26 Yoshitomi Pharmaceut Ind Ltd 縮合型ピラゾール化合物
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
JP2000501105A (ja) 1995-12-22 2000-02-02 デュポン ファーマシューティカルズ カンパニー 新規なインテグリン受容体アンタゴニスト
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
SK176598A3 (en) * 1996-06-25 2000-06-12 Pfizer Indazole derivatives, pharmaceutical composition on their base and methods of treatment
IL135900A0 (en) * 1997-11-04 2001-05-20 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeuticaly active compounds
DE19821002A1 (de) * 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,5- und 3-O-substituierte 1H-Indazole mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU4961499A (en) * 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
CA2335595A1 (en) 1998-06-29 2000-01-06 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
ATE252572T1 (de) * 1998-06-30 2003-11-15 Lilly Co Eli 5-ht1f agonisten
US6133290A (en) 1998-07-31 2000-10-17 Eli Lilly And Company 5-HT1F agonists
JP2002527438A (ja) * 1998-10-09 2002-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４，５−ジヒドロ−イソオキサゾール誘導体及びそれらの製薬学的使用
TR200101747T2 (tr) 1998-12-17 2001-11-21 F.Hoffmann-La Roche Ag 4- ve 5-alkinil oksindoller ve 4- ve 5-alkeniloksindoller.
CA2354402A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles as protein kinase inhibitors
TR200101858T2 (tr) 1998-12-17 2001-12-21 F.Hoffmann-La Roche Ag JNK protein kinaz inhibitörleri olarak 4-ariloksindoller
JP2000198734A (ja) 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
ATE425142T1 (de) 1999-04-23 2009-03-15 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
WO2000075118A1 (en) * 1999-06-03 2000-12-14 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)
MY133159A (en) 1999-08-13 2007-10-31 Vertex Pharma Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
KR100835700B1 (ko) 1999-08-19 2008-06-09 시그널 파머슈티컬스 인크 Ｊｎｋ억제제로서의 피라졸로안트론과 그 유도체 및 이를 함유하는 조성물
JP4847662B2 (ja) * 1999-09-14 2011-12-28 アベンティスユービー・セカンド・インコーポレイテッド Ｄ４拮抗剤として有用なチエノイソキサゾリル−およびチエニルピラゾリル−フェノキシ置換プロピル誘導体
EP1088821A1 (de) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmazeutisch wirksamer Sulfonamid Derivate
EP1088822A1 (de) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmazeutisch wirksame Sulfonyl Hydrazid-Derivate
EP1088815A1 (de) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutisch Aktive Sulfonyl-Aminosäurederivate
EP1110957A1 (de) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazolderivate und ihre Verwendung als JNK Modulatoren
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
ATE414079T1 (de) 2000-03-01 2008-11-15 Janssen Pharmaceutica Nv 2,4-disubstituierte thiazolyl derivate
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
ATE449763T1 (de) * 2001-04-16 2009-12-15 Eisai R&D Man Co Ltd 1h-indazolverbindungen die jnk hemmen

Also Published As

Publication number Publication date
EP1380576B1 (de) 2009-11-25
KR20040007497A (ko) 2004-01-24
AU2002255263B2 (en) 2006-12-14
US20050282880A1 (en) 2005-12-22
US7541376B2 (en) 2009-06-02
CN1300116C (zh) 2007-02-14
JP4535680B2 (ja) 2010-09-01
US7776890B2 (en) 2010-08-17
CN1512987A (zh) 2004-07-14
WO2002083648A1 (en) 2002-10-24
US20040127538A1 (en) 2004-07-01
EP1380576A4 (de) 2005-02-16
ATE449763T1 (de) 2009-12-15
US20090203691A1 (en) 2009-08-13
CA2440842A1 (en) 2002-10-24
EP1380576A1 (de) 2004-01-14
JPWO2002083648A1 (ja) 2004-08-05
US6982274B2 (en) 2006-01-03

Similar Documents

Publication Publication Date Title
DE60234510D1 (de) 1h-indazolverbindungen die jnk hemmen
ATE327230T1 (de) Piperidinverbindungen und diese enthaltenden medikamente
DE60230266D1 (de) Phenylpyridincarbonyl piperazinderivate
DE60315265D1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
NO20023456D0 (no) Nitrogenholdige forbindelser og farmasöytiske preparater inneholdende de samme
NO20033385D0 (no) Fuserte heterocykliske forbindelser
DE60129806D1 (de) Neue bizyklische verbindungen
SE0202838D0 (sv) Chemical compounds
UA83243C2 (ru) Соединения, которые ингибируют натриезависимый переносчик глюкозы
ATE503746T1 (de) Neue imidazolidinderivate
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
ATE401311T1 (de) Kondensierte heterozyklische verbindungen als petidase inhibitoren
ID25649A (id) Turunan-turunan sikloalkena, produksi serta penggunaannya
MY140489A (en) 1,2-di (cyclic) substituted benzene compounds
ATE271045T1 (de) Sauerstoffhaltige heterocyclische verbindungen
DE60239170D1 (de) Bicyclische Verbindungen
DK1209151T3 (da) 4-substituerede piperidinderivativer
ATE550332T1 (de) 4-imidazolin-2-onverbindungen als p38-map- kinaseinhibitors
ATE465153T1 (de) Neue indazolverbindungen mit kondensiertem ring
SE0402461D0 (sv) New process
EP1557407A4 (de) Neue alpha-ketoamidderivate und deren verwendung
WO2003043735A3 (de) P-funktionalisierte amine n-haltiger aromaten, deren herstellung und ihre verwendung in katalytischen reaktionen
ATE404548T1 (de) Cyclisches hemiacetalderivat und dessen anwendung
TH65651A (th) สารประกอบมาโลโนไนไทรล์ และการใช้ของสิ่งดังกล่าว
ATE311392T1 (de) Verbindungen und methoden zur inhibierung von mrp1

Legal Events

Date Code Title Description
8364 No opposition during term of opposition